ADMA BIOLOGICS, INC.
For the period ended Dec 31, 2024. Filed Mar 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 18, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ADMA Biologics, Inc. | ||
| Date: March 18, 2025 | By: | /s/ Adam S. Grossman |
|---|---|---|
| Name: Title: | Adam S. Grossman President and Chief Executive Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:
| Signature | Title | Date |
|---|---|---|
| /s/ Adam S. Grossman | ||
| Adam S. Grossman | President and Chief Executive Officer (Principal Executive Officer) and Director | March 18, 2025 |
| /s/ Brad Tade | ||
| Brad Tade | Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | March 18, 2025 |
| /s/ Steven A. Elms | ||
| Steven A. Elms | Chairman of the Board of Directors | March 18, 2025 |
| /s/ Dr. Jerrold B. Grossman | ||
| Dr. Jerrold B. Grossman | Vice Chairman of the Board of Directors | March 18, 2025 |
| /s/ Alison Finger | ||
| Alison Finger | Director | March 18, 2025 |
| /s/ Lawrence P. Guiheen | ||
| Lawrence P. Guiheen | Director | March 18, 2025 |
| /s/ Young T. Kwon | ||
| Young T. Kwon | Director | March 18, 2025 |
| /s/ Eduardo Rene Salas | ||
| Eduardo Rene Salas | Director | March 18, 2025 |
CONSOLIDATED FINANCIAL STATEMENTS
TABLE OF CONTENTS
| Page | |
| Reports of Independent Registered Public Accounting Firm (PCAOB ID 185) | F-3 |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID 596) | F-7 |
| Consolidated Balance Sheets as of December 31, 2024 and 2023 | F-8 |
| Consolidated Statements of Operations for the years ended December 31, 2024, 2023 and 2022 | F-9 |
| Consolidated Statements of Changes in Stockholders’ Equity for the years ended December 31, 2024, 2023 and 2022 | F-10 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2024, 2023 and 2022 | F-11 |
| Notes to Consolidated Financial Statements | F-12 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.